Recently in Funding Opportunities Category

The University of Minnesota Clinical and Translational Science Institute (CTSI), in partnership with the University's Department of Pediatrics and Children's Hospitals and Clinics of Minnesota, is now accepting applications for the 2014 Child Health Collaborative Grant Award. The groups teamed up to create this new grant program as part of a broader effort to support research partnerships among community and University child health researchers.

The program supports collaborative research that addresses important, unmet child health issues in Minnesota by developing and translating innovative, evidence-based health improvement strategies. Ultimately, the program aims to improve the health of children and adolescents throughout the state.

Applicants must involve at least two co-principal investigators: one from Children's, and one from the University of Minnesota. The application also must demonstrate active engagement with and input from an investigator based in the University of Minnesota Medical School's Department of Pediatrics. Proposals can be based on active partnerships, but applications that generate new partnerships are strongly encouraged. Junior investigators are also encouraged to apply.

Mandatory letters of intent are due by January 30, 2015. Investigative teams will then be invited to submit a full application. One award will be funded, with a two-year budget period spanning July 1, 2015 to June 30, 2017. The program will consider total budget requests of up to $200,000.

To learn more about the Child Health Collaborative Grant Award, download the RFA, and view other current CTSI funding opportunities, visit

For additional insight and suggestions for a successful proposal, feel free to contact the program's key collaborators: Dr. Mark Schleiss, CTSI Child Health Champion, or Dr. Rob Payne of Children's. Dr. Schleiss can be reached at, 612-626-9913 (office), or 612-356-4699 (cell), while Dr. Payne can be reached at or 612-813-6418 (office).

Investigators from the University of Minnesota and the Mayo Clinic have a new opportunity to advance their research, thanks to the launch of a collaborative grant program that is now accepting applications.

The University of Minnesota Clinical and Translational Science Institute (CTSI) and the Mayo Clinic Center for Clinical and Translational Science (CCaTS) established the Translational Product Development Fund (TPDF) program in conjunction with the Minnesota Partnership for Biotechnology and Medical Genomics (MNP).

The TPDF program supports the advancement of projects that have the potential to be commercialized, such as projects that aim to form a start-up company or create a license agreement with an established commercial entity. Ultimately, the program aims to impact the lives of Minnesotans by translating research discoveries into new therapies and treatment approaches for patients.

All full-time University of Minnesota faculty (all campuses) and Mayo Clinic Associate Consultant to Consultant investigators from the Rochester campus are invited to apply. Mandatory letters of intent (LOIs) are due by 5pm on December 19, 2014 (Cycle 1) and May 1, 2015 (Cycle 2), and must be submitted via an online form. Select applicants will be invited to submit full proposals.

The program offers two levels of possible funding:

  • Tier 1: Awards up to $50,000 in total direct costs to support projects that aim to establish scientific and technical merit, feasibility, and commercial potential.

  • Tier 2: Awards up to $200,000 to advance projects past the feasibility assessment as described in Tier 1, and toward the creation of a commercial entity or licensing agreement; applications for this tier require approval from program administration.

In addition, awardees will receive a customized project development team (PDT) to help advance projects along the translational development pathway.

To learn more about this grant program, download the RFA, and view other current CTSI funding opportunities, visit

CTSI is now accepting applications for two programs aimed at supporting translational researchers. The new Pediatric Medical Device Translational Grant Program will support the development of pediatric medical devices, while the KL2 Scholars Career Development Program will support U of M junior faculty investigators.

Pediatric Medical Device Translational Grant Program
This funding program supports the development of pediatric medical devices, with the ultimate goal of improving pediatric patient outcomes and quality of life through technology-driven medical solutions. The program's partners, CTSI's Office of Discovery and Translation (ODAT) and the Pediatric Device Innovation Consortium (PDIC), will provide funded investigators with work strategy guidance, frequent feedback, and access to comprehensive internal and external services. ODAT and PDIC anticipate funding up to three projects, awarding each a maximum of $50,000 for one year. Mandatory letters of intent are due April 10, 2014. Learn more and apply.

KL2 Scholars Career Development Program
This career development program provides mentorship, training, and funds to assistant professors (rank ≤ 6 years) conducting clinical and translational research. Up to one awardee will receive 75% salary support, up to $26,000 per year in research and travel funds for three years, training, and ongoing support from mentors and CTSI's Research Education, Training, and Career Development team. The structured training program aims to help awarded investigators be more successful, equipping them with skills to chart their academic career path, secure extramural funding, and pursue scholarly publications. Applications are due May 15, 2014 by 5pm. Learn more and apply.

U of M and community researchers now have new opportunities to fund their projects, thanks to three Request for Applications from the Clinical and Translational Science Institute (CTSI). CTSI anticipates awarding up to $795,000 in total funding to support as many as 21 research projects aimed at improving human health.

Grant programs fund a wide range of projects, from early-stage, translational research to clinical research to community-engaged research. Mandatory Letters of Interest for all programs are due by 5pm on Feb. 13, 2014, with full applications (by invitation) due April 9, 2014.

Translational Grant Program (for basic science research in the early stages of translation)
This funding program helps drive research that translates basic science discoveries into patient benefit, with the overarching goal of improving human health. In addition to funds, awarded projects will also receive a project development team with the appropriate expertise to help determine project milestones, identify key gaps, and strengthen the project's likelihood of advancing toward new therapeutics, diagnostics, devices, or treatment approaches. CTSI anticipates funding up to 8 projects, awarding each with approximately $50,000. Learn more and apply.

Research Services Pilot Funding Program (for clinical research projects)
This funding program supports focused clinical research pilot projects and is designed to poise U of M researchers for future success by providing pilot data for extramural funding and publications. Funded investigators can access a wide range of services for planning, implementing, conducting, and analyzing studies, from consultations and support to clinical facilities, staff, and procedures. CTSI anticipates funding up to 5 projects, awarding up to $25,000 each. Learn more and apply.

Community Health Collaborative Grants Program (for community-engaged research projects)
This funding program supports community-university pilot research projects that address important health issues identified by Minnesota communities. Awards are designed to stimulate high-impact research, while building and sustaining long-term partnerships between U of M researchers and community representatives. CTSI can help interested applicants identify potential research partners, and will award a total of approximately $270,000 to up to 8 proposals. Learn more and apply.

For questions or more information, please contact CTSI's Research Navigator at or 612.625.2874.

The National Center for Advancing Translational Sciences (NCATS) is announcing an open opportunity to submit proposals to collaborate with the Therapeutics for Rare and Neglected Diseases (TRND) program.

The TRND program performs preclinical and early clinical development of new drugs for rare and neglected tropical diseases, and develops new technologies and paradigms to improve the efficiency of therapeutic development for these disorders. TRND seeks collaborative partnerships with academic laboratories, not-for-profit organizations, and for-profit companies. This is not a grant program, and no extramural funds will be provided.

Please visit the TRND website and the related NIH Guide Notice for complete details regarding program scope, eligibility, and application process.

Letters of Intent are due no later than September 16, and full proposals must be submitted by September 30.